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Hepatitis C virus (HCV) infection is a serious public health problem, since 80% to 85% of
HCV carriers develop a persistent infection that can progress into liver cirrhosis and
hepatocarcinoma. Considering that the response of hepatitis C patients to combination therapy
with interferon and ribavirin depends on HCV characteristics as well as on host features, we made
a retrospective analysis of demographic and anthropometrical data and HCV genotype distribution
of chronic hepatitis C patients treated in public and private reference centers in Brazil. The
medical records of 4,996 patients were reviewed, 81% from public and 19% from private
institutions. Patients’ median age was 46 years, and there was a higher prevalence of male (62%)
and white patients (80%). The analysis of HCV-infecting strains showed a predominance of
genotype 1 (64%) over genotypes 2 and 3. The patients’ mean weight was 70.6 kg, and 65% of the
patients weighed less than 77kg. Overweight and obesity were observed in 37.8% and 13.6% of
the patients, respectively. Since a body weight of 75 kg or less has been considered an independent
factor that significantly increases the odds of achieving a sustained virological response, the
Brazilian population seems to have a more favorable body weight profile to achieve a sustained
response than the American and European populations. The finding that 65% of chronic hepatitis
C patients have a body weight of  77 kg or less may have a positive pharmacoeconomic impact on
the treatment of genotype 1 HCV patients with weight-based doses of peginterferon.
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Hepatitis C virus (HCV) was identified in 1989 [1];
it is responsible for about 90% of the so-called non-A
non-B hepatitis. It is a RNA virus of the Flaviviridae
(Flavivirus) family and Hepacivirus gender [2] that is
primarily transmitted through infected blood [3].
HCV infection affects about 170 million people
worldwide and is currently one of the major public health
problems in Brazil and in the world [4]. According to
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the Brazilian Hepatology Society, local epidemiological
information is still incipient. Brazilian studies on this
subject have been predominantly aimed at risk groups
(drug addicts [5], patients undergoing hemodialysis [6]
and blood donors [7-12]). So far, only a few
investigators have addressed the prevalence of hepatitis
C in the general population [13,14].
Focaccia et al. [13] made a populational,
randomized and stratified study, and reported a
prevalence of 1.42% of HCV carriers in the city of
São Paulo, with rates increasing with age, reaching over
3.5% in individuals aged 30 years and over. In spite of
HCV’s low infectivity and slow replication rate, 80%
to 85% of the patients will develop a persistent,
asymptomatic (or oligosymptomatic) infection that may
progress into liver cirrhosis in approximately 20% of
the patients and into hepatocellular carcinoma in part
of these cases [15,16].
Considering that the response of HCV patients to
combination therapy with interferon and ribavirin
depends on intrinsic HCV characteristics, such as
genotype, as well as on host features such as sex, age,
the degree of liver fibrosis [17] and body weight [18],
we made a retrospective analysis of demographic and
anthropometrical data and of HCV genotype
distribution of chronic hepatitis C patients treated in
public and private reference centers in Brazil.
Material and Methods
A retrospective analysis was made of the medical
records of HCV carriers older than 14 years followed
up in 11 reference public institutions and four specialized
private hospitals. Medical records of HCV patients
treated within the two years preceding the study were
sequentially included; 74% of the hepatitis C diagnoses
were made after 1998. One or more health
professionals designated by the principal investigator
reviewed the medical records and transferred selected
data into a “Data Collection Form”.
The following data were collected: number of the
medical record, patient’s initials, age, sex, color, weight,
height, HCV genotype and origin (geographic area,
private versus public institution) and entered in a
computerized database that generated a report with
descriptive statistics for all variables. After data
collection, a second review was performed for a sample
of 10% of the records by comparatively checking the
information in the data collection forms and the
respective source documents for quality assurance of
the collection process. The χ2 test was used for statistical
analysis and significant differences were considered
when p < 0.05.
Results
Demographic data
The medical records of 4,996 patients were
reviewed, and 4,041 (81%) were from public and 955
(19%) from private institutions. Most data were
collected in the southeast region of the country (69%),
27% in the south region and 4% in the northeast region.
The patients were 15 to 98 years old, with a median
age of 46 years, 50 years for females (16 - 87 years)
and 44 years for males (15 - 98 years). Only 0.5% of
the patients were 14 to 19 years old, 27.5% were 20
to 39 years old, 58% were 40 to 59 years old and
14% were 60 years or older. Sixty two percent were
males and 38% were females. Eighty percent of the
patients were white (Table 1).
HCV genotype
Information on the HCV genotype was available
for only 27% of the medical records. The following
distribution was observed: 64% for genotype 1, 3%
for genotype 2 and 33% for genotype 3. The highest
prevalence of genotype 3 was observed in the south
region (Figure 1).
Anthropometrical data
Information on patients’ weight was available for
72% of the medical records. The patients mean weight
was 70.6 kg, and it was significantly higher in males
Anthropometrical Data of Brazilian HCV Patients
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Table 1. Demographic data of 4,996 Brazilian chronic hepatitis C patients
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Age (Median, Range) 46 yrs (15 – 98 yrs)
Female 50 yrs (16 – 87 yrs)
Male 44 yrs (15 – 98 yrs)
Age distribution
14 - 19 yrs 0.5 %
20 - 39 yrs 27.5 %
40 - 59 yrs 58.0 %
> 60 yrs 14.0 %
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than in females (76.7 kg versus 64.9 kg, respectively)
(p<0.0001). Most patients (65%) weighed less than
77kg (Figure 2). No significant differences were
observed between weight distributions among the three
regions of the country (Figure 3) or between patients
followed in public and private institutions (Figure 4).
Height data was available for 30.7% of the medical
records, making it possible to calculate body mass index
(BMI) for these patients. BMI was normal in 47.9%
of the patients, whereas overweight and obesity were
observed in 37.8% and 13.6% of the patients,
respectively (Table 2).
Discussion
It is well known that intrinsic HCV characteristics
can influence the rates of sustained virological response
(SVR) to interferon-based therapy; however, host
features may also interfere with response to treatment
[17,18]. Though retrospective studies might be
inaccurate because of the way data are retrieved rather
than how they are recorded, they are often the only
source of information, especially in countries like Brazil,
where prospective populational studies are not always
feasible.
The median age of 46 years for the chronic hepatitis
C patients in this study was very close to that reported
in other Brazilian surveys by Bassit et al. (mean age of
47 years) [19] and by Medeiros-Filho et al. (mean age
of 49.7 years). Similarly to the Medeiros-Filho’s sample,
most of the patients who were followed-up were 40 to
60 years old (60 and 58%, respectively) [20].
As reported by Bassit et al. [19], there was a higher
prevalence of males (62%). Other publications have
already shown this prevalence, reporting rates
ranging from 64% to 72% [21-24]. This result
probably reflects the characteristics of the blood
donor population, constituted of presumably healthy
adult males who seek medical assistance after being
diagnosed in blood banks. In addition, it is known
that drug abuse and sexual behaviors that predispose
to sexually transmittable disease are more common
among males [25].
Although HCV genotype determines the duration
of the combination therapy with interferon-α and
ribavirin, HCV genotyping was carried out in only 27%
of the patients under treatment. The distribution of
HCV infecting strains was similar to that previously
reported in other studies [19,26], with prevalence of
genotype 1 (64%) over genotypes 2 and 3. The regional
genotype distribution also confirmed the higher
prevalence of genotype 3 in the south region reported
by Campiotto et al. [26].
The scarcity of Brazilian anthropometrical data
makes the interpretation of weight and BMI data in
chronic HCV patients difficult. The percentage of obese
and overweight patients was 51.4% in our sample,
whereas a survey carried out in 1997 in southeast and
northeast Brazil found an overweight and obesity
prevalence of 38.5% [27]. The increased prevalence
of overweight and obese patients observed in our study
compared to that of 1997 might be due to regional
differences; however, taking into consideration the
influence of obesity associated with liver steatosis on
the response to the combination therapy [28], further
studies are required to clarify this issue.
Analysis of the results of phase III clinical trials with
interferon α-2b have shown that SVR rates are greatly
influenced by body weight, since smaller body weights
were associated with higher sustained response rates
[29]. The impact of body weight on SVR was also
reported by a PEG IFN α-2a monotherapy study [30]
as well as by a PEG IFN α-2a plus ribavirin study,
where three factors were shown to independently and
significantly increase the odds of achieving a SVR: a
non -1 HCV genotype, age = 40 years and body weight
= 75 kg [18].
This is the first clinical study to evaluate the weight
of chronic hepatitis C patients in Brazil. The  mean
weight of 70.6 kg observed in this survey suggests that
the Brazilian population has a more favorable body
weight profile to achieve a SVR than the American and
European populations, whose mean weight has ranged
from 73 kg to 82 kg [17,18,31,32] in previous studies
with ribavirin and interferon or peginterferon. We also
found that 65% of the chronic hepatitis C patients had
a body weight of 77 kg or less. This finding may have
Anthropometrical Data of Brazilian HCV Patients
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Figure 2. Distribution of chronic hepatitis C patients according to body weight.
Figure 3. Weight distribution of chronic hepatitis C patients according to geographic region.
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Figure 4. Weight distribution of chronic hepatitis C patients according to reference center (public or private).
Table 2. Body Mass Index of 1,533 Brazilian chronic hepatitis C patients
Body mass index  %
 <25  (normal) 47.9
25-29.9 (overweight) 37.8
30-40 (obesity) 13.6
>40 (morbid obesity) 0.7
a positive pharmacoeconomic impact on the treatment
of patients infected by genotype 1 with weight-based
dosing of peginterferon. The inclusion of an economic
perspective has become an increasingly accepted
component to establish health care policies and planning
[33], and knowing the population’s characteristics may
be useful when allocating scarce public health
resources.
Therefore, it is essential that governmental strategies
are developed to allow a better understanding of the
HCV population and hence optimize resources in this
important public health care problem.
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